Aurora Cannabis Stands Its Ground as Curaleaf’s Sweetened Bid Falls Short

EDMONTON – Aurora Cannabis Inc. confirmed that its board, acting unanimously on the recommendation of its Special Committee of independent directors, is advising shareholders to REJECT the revised hostile takeover offer from Curaleaf Holdings Inc. and to TAKE NO ACTION ahead of a parallel strategic review now underway.

Curaleaf filed its enhanced offer on October 6, raising the implied consideration from $4 to $5 per Aurora share, structured as 0.4013 Curaleaf shares plus $1.00 in cash, with the overall cap raised from $5 to $6. On the surface, that reads as a 25% improvement. In practice, the actual cash increase amounts to just $0.25 per share. The remainder of the sweetener arrives as additional Curaleaf equity, meaning the value Aurora shareholders would actually receive stays directly tied to the performance of a company carrying approximately $1 billion in debt. Aurora, for its part, is currently debt-free.

“Aurora is debt-free with a strong cash position, and we believe the revised Hostile Bid continues to ask shareholders to give up that strength, and their future upside, at a discount,” said Miguel Martin, Executive Chairman and CEO, in the company’s press release. The determination follows careful review by the Board and Special Committee, including an updated inadequacy opinion from Aurora’s independent financial advisor confirming that the revised consideration is insufficient from a financial standpoint.

The board also flagged what may be the bid’s most structurally unusual feature. A significant portion of the cash consideration would, in effect, be funded by Aurora shareholders’ own cash through Aurora’s balance sheet. In plain terms, Curaleaf is proposing to partially acquire Aurora using Aurora’s own money, while keeping the downside risk squarely with Aurora’s shareholders.

On synergies, Aurora’s board challenged Curaleaf’s projections, arguing that even if the claimed benefits were fully realized, substantially all of the value would accrue to Curaleaf’s existing shareholders rather than to Aurora’s. Curaleaf had cited at least $40 million in expected annual cost synergies as part of its rationale – a figure Aurora’s advisors found insufficiently substantiated.

Running in parallel, Aurora’s Special Committee has entered into confidentiality and standstill agreements with multiple third parties, each of whom is currently conducting due diligence on Aurora’s business. The company has said it cannot predict with certainty what alternatives may emerge but has emphasized that tendering early could negatively affect the possibility of a superior outcome. Shareholders have [at least] until December 4 to decide.

Curaleaf Chairman and CEO Boris Jordan pushed back sharply, characterizing Aurora’s response as “grossly inadequate and negligent to its shareholders.” Curaleaf has pointed to an 86% premium above Aurora’s unaffected share price and the breadth of a combined entity spanning operations across 17 countries, with more than $1.5 billion in LTM revenue and nearly $350 million in adjusted EBITDA.

The core of Aurora’s argument is structurally sound. Being acquired partly with one’s own cash, in exchange for equity in a heavily leveraged buyer, is a trade that concentrates risk with the selling shareholders while the acquirer preserves optionality. The decisive variable now is what Aurora’s data room produces. If a competing offer surfaces before December 4, the board’s patience will look prescient. If it doesn’t, the calculus changes fast. Either outcome will tell the Cannabis sector something important about what a truly debt-free, globally certified medical Cannabis operator actually commands in today’s market. and that number has not yet been established.